NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT01695941 2026-03-18
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05627245 2026-03-18
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07480837 2026-03-18
Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Active not recruiting
NCT05397496 2026-03-17
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Phase 1 Active not recruiting
NCT06561425 2026-03-16
Atalanta-1
Galapagos NV
Phase 1/2 Active not recruiting
NCT05784441 2026-03-13
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05540340 2026-03-06
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04842877 2026-02-19
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting